Navigation Links
Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Date:6/17/2010

WAYNE, N.J., June 17 /PRNewswire/ -- Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.  Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer and agents targeting the Wnt pathway have the potential to be developed as pan-tumor drugs.  The strategic alliance provides Bayer with the option to exclusively license antibody and protein therapeutic product candidates at any point up to the completion of Phase I testing.  In addition, Bayer and OncoMed will share technology and know-how to discover and develop small molecule inhibitors of the pathway.

"At Bayer, we recognize the high unmet medical need for cancer treatments.  This collaboration with OncoMed demonstrates our commitment to developing new and innovative treatment options," said Prof. Andreas Busch, Head of Global Drug Discovery and Member of the Board of Management at Bayer. "The development of anti-cancer stem cell therapeutics together with OncoMed is a highly innovative approach with the potential to perfectly complement our oncology portfolio.  Anti-cancer stem cell research could turn out as one of the missing pieces in today's cancer therapy."

"Our alliance with Bayer represents a major opportunity to discover and develop an entirely new class of anti-cancer stem cell therapeutics with one of the leading pharmaceutical companies in the world.  Bayer shares our vision for the potential of anti-cancer stem cell therapeutics, and we look forward to working closely with them," said Paul J. Hastings, President and CEO of
'/>"/>

SOURCE Bayer HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bayer Sues Teva and Barr for False Advertising and Patent Infringement in Connection with Tevas Generic Oral Contraceptive Gianvi™
2. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
3. Bayer Diabetes Care Introduces DIDGET In the US
4. FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
5. Bayers A1CNow(R) SELFCHECK At-Home A1C System Now Available In Local Pharmacies
6. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
7. Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels
8. Bayer Express Your Simple Win Creativity Contest Grand Prize Winners Announced
9. Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
10. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
11. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
(Date:9/16/2014)... -- Russia,s pharmaceutical ... Pharma 2020 Strategy provides incentives for local producers to ... foreign markets. These trends, however, were affected by recent ... political and economic sanctions imposed on Russia ... Russia responded to the US ...
(Date:9/16/2014)... Sept. 16, 2014 Surgeons at The Children,s ... a case report the first successful use of a ... year-old boy with failing Fontan circulation to bridge him ... 3 years old, the patient received a Fontan circulation ... single ventricle. "The Fontan operation is the final planned ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4Global Medicines for Russia 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3
... and PRINCETON, N.J., Jan. 31, 2011 Qforma, the leading ... health sciences industry, today announced the appointments of Ted Pine ... Michael Murphy as Software Engineer. "As Qforma ... optimize service to our pharmaceutical industry customers, we welcome the ...
... 2011 OXIS International, Inc., (OTC Bulletin Board: ... favorable final results from an initial clinical study to ... joint health formula, launched commercially in December 2010. ... statistically significant after as little as one week of ...
Cached Medicine Technology:Qforma, Leading Provider of Healthcare Analytics, Announces Three New Appointments 2Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 2Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 3Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 4
(Date:9/16/2014)... hold great promise in helping people to reach ... devices help the wearers improve their wellness by ... information is organized into companion computer programs and ... quickly growing market for these devices, researchers at ... analyzed 13 of these activity monitors, such as ...
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Although magnesium sulfate is ... preterm delivery, new research suggests it won,t provide any ... effects of magnesium sulfate given to pregnant women, researchers ... behavioral, growth or functional outcomes among those children when ... old. The new findings don,t negate the fact ...
(Date:9/16/2014)... radiation therapy as part of breast conservation is ... hormone-receptor positive (HR+) invasive breast cancer. A new ... however, shows that combination may not be necessary ... , The results, which Fox Chase researchers presented ... Annual Meeting on Sunday, September 14, suggest that ...
(Date:9/16/2014)... September 16, 2014 Programs and policies ... hundreds of billions of dollars in savings for the ... the Commonwealth Fund. To help spur these types of ... to 10 collaborative groups from across the country to ... http://bit.ly/1wo4gsa ) - a handbook designed to assist groups ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Who:, The ... Anschutz Medical Campus and Children’s Hospital Colorado ... is the country’s leading pulmonary hypertension association that works to ... a disease of the lungs that affects the functioning of ... treatment, mean survivability is only 2.8 years. , What:, ...
Breaking Medicine News(10 mins):Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... June 30 Standard & Poor,s will make the,following changes ... the,close of trading on Wednesday, July 2:, -- S&P ... replace Getty Images Inc. (NYSE: GYI ) in the ... replace IDEXX Laboratories in the S&P,SmallCap 600. Getty Images is ...
... findings as fact , , MONDAY, June 30 (HealthDay News) -- ... HDL cholesterol and loss of memory. , The study, which has ... percent increased loss of memory on a word test for those ... with the highest levels. By age 60, the rate of memory ...
... than placebo, one expert says , , MONDAY, June 30 ... of placing intravenous (IV) lines in children, Canadian researchers ... by 34 percent in children getting IV lines when ... rate of inserting the lines, said lead researcher Dr. ...
... for two adults? Experts consider this question alongside new ... Liver Transplantation , a journal by John Wiley ... Wiley Interscience ( www.interscience.wiley.com ). , The shortage of ... increase opportunities for those in need of a transplant. ...
... researchers at the Ocean University of China has developed and ... can accurately measure wind speed and direction over large areas ... weather forecasting and sports. , As described in the ... published by the Optical Society, the mobile lidar station can ...
... June 30 Robbins & Myers, Inc.,(NYSE: RBN ... for the third quarter,results conference call scheduled today, June ... or 1-617-614-3525,with ID# 84552408. Replays of the call can ... # 63192398., Robbins & Myers, Inc. is a ...
Cached Medicine News:Health News:Standard & Poor's Announces Changes to U.S. Indices 2Health News:Standard & Poor's Announces Changes to U.S. Indices 3Health News:Research Links Low HDL Levels With Memory Loss 2Health News:Spray Cuts Kids' Pain When Getting IVs 2Health News:Experts examine challenges of split liver transplantation 2Health News:New technology may help Olympic sailing 2
19 Gauge. Reusable. Block of 4 each....
18 gauge curved. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 23 gauge, stainless steel probes with blunt tips. Probes are 18 cm (7.0 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto the ...
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
Medicine Products: